Literature DB >> 21911837

Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia.

Xiao-Jie Yan1, Igor Dozmorov, Wentian Li, Sophia Yancopoulos, Cristina Sison, Michael Centola, Preetesh Jain, Steven L Allen, Jonathan E Kolitz, Kanti R Rai, Nicholas Chiorazzi, Barbara Sherry.   

Abstract

Individual cytokines and groups of cytokines that might represent networks in chronic lymphocytic leukemia (CLL) were analyzed and their prognostic values determined. Serum levels of 23 cytokines were measured in 84 patients and 49 age-matched controls; 17 levels were significantly elevated in patients. Unsupervised hierarchical bicluster analysis identified 3 clusters (CLs) of highly correlated but differentially expressed cytokines: CL1 (CXCL9, CXCL10, CXCL11, CCL3, CCL4, CCL19, IL-5, IL-12, and IFNγ), CL2 (TNFα, IL-6, IL-8, and GM-CSF), and CL3 (IL-1β, IL-2, IL-4, IL-15, IL-17, and IFNα). Combination scores integrating expression of CL1/CL2 or CL1/CL3 strongly correlated (P < .005) with time-to-first-treatment and overall survival (OS), respectively. Patients with the worst course had high CL1 and low CL2 or CL3 levels. Multivariate analysis revealed that CL1/CL2 combination score and immunoglobulin heavy chain variable region mutation status were independent prognostic indicators for time-to-first-treatment, whereas CL1/CL3 combination score and immunoglobulin heavy chain variable region mutation status were independent markers for OS. Thus, we identified groups of cytokines differentially expressed in CLL that are independent prognostic indicators of aggressive disease and OS. These findings indicate the value of multicytokine analyses for prognosis and suggest therapeutic strategies in CLL aimed at reducing CL1 and increasing CL2/CL3 cytokines.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21911837      PMCID: PMC3217404          DOI: 10.1182/blood-2011-03-342436

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  48 in total

Review 1.  Chronic lymphocytic leukemia.

Authors:  Nicholas Chiorazzi; Kanti R Rai; Manlio Ferrarini
Journal:  N Engl J Med       Date:  2005-02-24       Impact factor: 91.245

Review 2.  Molecular and cellular mechanisms of CLL: novel therapeutic approaches.

Authors:  Lisa Pleyer; Alexander Egle; Tanja Nicole Hartmann; Richard Greil
Journal:  Nat Rev Clin Oncol       Date:  2009-06-02       Impact factor: 66.675

3.  Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22.

Authors:  Paolo Ghia; Giuliana Strola; Luisa Granziero; Massimo Geuna; Giuseppe Guida; Federica Sallusto; Nancy Ruffing; Licia Montagna; Paola Piccoli; Marco Chilosi; Federico Caligaris-Cappio
Journal:  Eur J Immunol       Date:  2002-05       Impact factor: 5.532

Review 4.  The role of chemokines in B cell chronic lymphocytic leukaemia: pathophysiological aspects and clinical impact.

Authors:  Percy Schröttner; Marion Leick; Meike Burger
Journal:  Ann Hematol       Date:  2009-12-18       Impact factor: 3.673

5.  Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome.

Authors:  L Fayad; M J Keating; J M Reuben; S O'Brien; B N Lee; S Lerner; R Kurzrock
Journal:  Blood       Date:  2001-01-01       Impact factor: 22.113

6.  A distinct multicytokine profile is associated with anti-cyclical citrullinated peptide antibodies in patients with early untreated inflammatory arthritis.

Authors:  Carol A Hitchon; Philip Alex; Lawrence B Erdile; Mark B Frank; Igor Dozmorov; Yuhong Tang; Keng Wong; Michael Centola; Hani S El-Gabalawy
Journal:  J Rheumatol       Date:  2004-12       Impact factor: 4.666

7.  Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia.

Authors:  Raymond Lai; Susan O'Brien; Taghi Maushouri; Anna Rogers; Hagop Kantarjian; Micheal Keating; Maher Albitar
Journal:  Cancer       Date:  2002-09-01       Impact factor: 6.860

8.  CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival.

Authors:  Antonella Zucchetto; Dania Benedetti; Claudio Tripodo; Riccardo Bomben; Michele Dal Bo; Daniela Marconi; Fleur Bossi; Debora Lorenzon; Massimo Degan; Francesca Maria Rossi; Davide Rossi; Pietro Bulian; Vito Franco; Giovanni Del Poeta; Silvia Deaglio; Gianluca Gaidano; Francesco Tedesco; Fabio Malavasi; Valter Gattei
Journal:  Cancer Res       Date:  2009-04-21       Impact factor: 12.701

Review 9.  New insights into the pathogenesis of chronic lymphocytic leukemia.

Authors:  Ulf Klein; Riccardo Dalla-Favera
Journal:  Semin Cancer Biol       Date:  2010-10-26       Impact factor: 15.707

10.  Interleukin-15 promotes the growth of leukemic cells of patients with B-cell chronic lymphoproliferative disorders.

Authors:  L Trentin; A Cerutti; R Zambello; R Sancretta; C Tassinari; M Facco; F Adami; F Rodeghiero; C Agostini; G Semenzato
Journal:  Blood       Date:  1996-04-15       Impact factor: 22.113

View more
  45 in total

1.  Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia.

Authors:  Stefania Fiorcari; Silvia Martinelli; Jenny Bulgarelli; Valentina Audrito; Patrizia Zucchini; Elisabetta Colaci; Leonardo Potenza; Franco Narni; Mario Luppi; Silvia Deaglio; Roberto Marasca; Rossana Maffei
Journal:  Haematologica       Date:  2014-11-14       Impact factor: 9.941

Review 2.  B cell receptor signaling in chronic lymphocytic leukemia.

Authors:  Jan A Burger; Nicholas Chiorazzi
Journal:  Trends Immunol       Date:  2013-08-05       Impact factor: 16.687

Review 3.  Role of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy.

Authors:  Ting-Ting Han; Lei Fan; Jian-Yong Li; Wei Xu
Journal:  Cancer Biol Ther       Date:  2013-10-22       Impact factor: 4.742

4.  Circulating immune/inflammation markers in Chinese workers occupationally exposed to formaldehyde.

Authors:  Wei Jie Seow; Luoping Zhang; Roel Vermeulen; Xiaojiang Tang; Wei Hu; Bryan A Bassig; Zhiying Ji; Meredith S Shiels; Troy J Kemp; Min Shen; Chuangyi Qiu; Boris Reiss; Laura E Beane Freeman; Aaron Blair; Christopher Kim; Weihong Guo; Cuiju Wen; Laiyu Li; Ligia A Pinto; Hanlin Huang; Martyn T Smith; Allan Hildesheim; Nathaniel Rothman; Qing Lan
Journal:  Carcinogenesis       Date:  2015-04-23       Impact factor: 4.944

5.  Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia.

Authors:  Qingsong Yin; Mariela Sivina; Harlan Robins; Erik Yusko; Marissa Vignali; Susan O'Brien; Michael J Keating; Alessandra Ferrajoli; Zeev Estrov; Nitin Jain; William G Wierda; Jan A Burger
Journal:  J Immunol       Date:  2017-01-11       Impact factor: 5.422

6.  Increased risk of axial fractures in patients with untreated chronic lymphocytic leukemia: a population-based analysis.

Authors:  Adam J Olszewski; Roee Gutman; Charles B Eaton
Journal:  Haematologica       Date:  2016-08-04       Impact factor: 9.941

7.  IL-10 production by CLL cells is enhanced in the anergic IGHV mutated subset and associates with reduced DNA methylation of the IL10 locus.

Authors:  S Drennan; A D'Avola; Y Gao; C Weigel; E Chrysostomou; A J Steele; T Zenz; C Plass; P W Johnson; A P Williams; G Packham; F K Stevenson; C C Oakes; F Forconi
Journal:  Leukemia       Date:  2016-11-28       Impact factor: 11.528

8.  Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697).

Authors:  Lisa H Butterfield; Fengmin Zhao; Sandra Lee; Ahmad A Tarhini; Kim A Margolin; Richard L White; Michael B Atkins; Gary I Cohen; Theresa L Whiteside; John M Kirkwood; David H Lawson
Journal:  Clin Cancer Res       Date:  2017-05-23       Impact factor: 12.531

9.  Activation of the B-cell receptor successively activates NF-κB and STAT3 in chronic lymphocytic leukemia cells.

Authors:  Uri Rozovski; David M Harris; Ping Li; Zhiming Liu; Preetesh Jain; Ivo Veletic; Alessandra Ferrajoli; Jan Burger; Philip Thompson; Nitin Jain; William Wierda; Michael J Keating; Zeev Estrov
Journal:  Int J Cancer       Date:  2017-08-04       Impact factor: 7.396

10.  The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL.

Authors:  Ian W Flinn; Peter Hillmen; Marco Montillo; Zsolt Nagy; Árpád Illés; Gabriel Etienne; Julio Delgado; Bryone J Kuss; Constantine S Tam; Zoltán Gasztonyi; Fritz Offner; Scott Lunin; Francesco Bosch; Matthew S Davids; Nicole Lamanna; Ulrich Jaeger; Paolo Ghia; Florence Cymbalista; Craig A Portell; Alan P Skarbnik; Amanda F Cashen; David T Weaver; Virginia M Kelly; Barry Turnbull; Stephan Stilgenbauer
Journal:  Blood       Date:  2018-10-04       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.